Louis Aronne
Internal Medicine · New York, NYNPI 1316077050
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.6%. 2025 is the largest year on record at $87,286, 2.3 times the $38,088 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $1000.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$65K
- Novo Nordisk$53K
- Novo Nordisk AS$48K
- Veru Inc.$41K
- Pfizer$35K
- Boehringer Ingelheim$17K
- plus $57K from 12 others
Across 335 payments — averaging $3442.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$909K
- Novo Nordisk AS$180K
- Janssen Research & Development, LLC$62K
- Eisai Inc.$2K
What the payments were for
- Consulting fees$154,15049%
- Speaking & faculty fees$77,45524%
- Travel & lodging$75,24924%
- Food & beverage$9,3693%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 88 | $65,272 |
| Novo Nordisk | 110 | $53,359 |
| Novo Nordisk AS | 18 | $47,595 |
| Veru Inc. | 1 | $41,230 |
| Pfizer | 20 | $34,735 |
| Boehringer Ingelheim | 17 | $16,598 |
| Amgen | 10 | $14,635 |
| Zealand Pharma A/s | 8 | $11,376 |
| Sanofi-aventis U.S. LLC | 9 | $10,340 |
| F. Hoffmann-la Roche AG | 5 | $7,291 |
| Currax Pharmaceuticals LLC | 3 | $3,262 |
| Astrazeneca UK Limited | 3 | $3,142 |
| Jazz Pharmaceuticals Inc. | 1 | $2,975 |
| Genentech USA, Inc. | 2 | $2,968 |
| Shionogi Inc | 1 | $1,118 |
| Lilly USA, LLC | 18 | $329 |
| La Jolla Pharmaceutical Company | 1 | $34 |
| Intra-sana Laboratories | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$316,287 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $74,665 |
| MounjaroTirzepatide | 39 | $57,660 |
| JardianceEmpagliflozin | 12 | $12,456 |
| Metformin Hcl ErMetformin Hcl | 31 | $394 |
| Topiramate | 18 | $352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $53,359 | $74,66560 claims |
| Lilly USA, LLCMounjaro | $329 | $57,66039 claims |
| Boehringer IngelheimJardiance | $16,598 | $12,45612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.